Core Viewpoint - A class action securities lawsuit has been filed against Semler Scientific, Inc. for alleged securities fraud affecting investors between March 10, 2021, and April 15, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Semler Scientific failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act, while discussing potential violations in hypothetical terms [3]. - The complaint alleges that the public statements made by the defendants were materially false and misleading during the relevant time period [3]. Group 2: Investor Information - Investors who suffered losses in Semler Scientific during the specified timeframe have until October 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - Investors have until September 22, 2025, to request to lead the case in the U.S. District Court for the Central District of California, under the case caption Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2]. Financial Performance - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during the relevant period when the company promoted strong sales [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Points - Wu Jian, a former employee of Two Sigma, faces civil and criminal charges from the SEC and DOJ for wire fraud, securities fraud, and money laundering [1] - Wu Jian's actions led to significant financial losses for clients and unauthorized modifications to investment models [7][8] Group 1: Background and Career - Wu Jian graduated from Tsinghua University in 2011 and obtained a PhD from Cornell University in 2017 [2] - He interned at Citadel and joined Two Sigma in April 2018, quickly rising to Senior Vice President by January 2023 [4] Group 2: Allegations and Financial Impact - Between November 2021 and August 2023, Wu Jian manipulated at least 14 investment models, misleading Two Sigma about their performance [7] - His unauthorized changes resulted in client losses of at least $165 million, while some funds gained $450 million, primarily benefiting company executives and employees [7] - Wu Jian received $23.5 million in compensation in 2022, part of which was used to purchase a multi-million dollar apartment in Manhattan [8] Group 3: Company Response - Two Sigma terminated Wu Jian in 2024 and is compensating clients for their losses [9] - The company has rescinded Wu Jian's $8 million performance bonuses for 2021 and 2022 but has not recovered the $17.8 million in cash bonuses he received [8]

Core Viewpoint - Tronox Holdings PLC is facing a class action lawsuit due to significant financial losses and misleading statements made by the company regarding its business operations and financial outlook during the Class Period from February 12, 2025, to July 30, 2025 [1][4]. Financial Performance - On July 30, 2025, Tronox reported a substantial decline in sales for its TiO2 product, attributing this to a "softer than anticipated coatings season and heightened competitive dynamics" [2]. - The company revised its 2025 financial outlook, lowering its full-year revenue guidance and cutting its dividend by 60% [2]. Stock Market Reaction - Following the release of the disappointing financial results, Tronox's stock price plummeted by $1.95, or 37.9%, closing at $3.19 per share on July 31, 2025, resulting in significant losses for investors [3]. Allegations in the Lawsuit - The class action complaint alleges that Tronox made materially false and misleading statements and failed to disclose adverse facts about its business and operations [4]. - Specific allegations include the company's inability to accurately forecast demand for its products and the promotion of unrealistic margin projections based on expected sales volume increases [4].

Core Viewpoint - A class action lawsuit has been initiated against LifeMD, Inc. on behalf of investors who purchased the company's securities between May 7, 2025, and August 5, 2025, seeking to recover losses incurred during this period [1][3]. Summary by Sections Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements regarding LifeMD's competitive position and financial guidance for 2025, failing to account for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. Investor Information - Investors who suffered losses have until October 27, 2025, to seek appointment as lead plaintiff and can visit the provided link for more information on eligibility for potential recovery [2]. Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities class action lawsuits, representing both individual and institutional investors [4].

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud impacting investors between February 26, 2025, and August 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management provided misleading positive statements while concealing adverse facts about the company's growth, particularly regarding the health of its CEO and its impact on deal closures [2]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health [2]. - Following the announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. for alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations and Company Performance - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the company overstated the demand for its products, which resulted in an inability to meet previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - RxSight, Inc. specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its main product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Financial Performance and Issues - During the relevant period, RxSight promoted strong sales of its LAL and Light Delivery Device (LDD) but failed to disclose "adoption challenges" and a slowdown in LAL utilization that began in 2024 [4]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast due to a "softening" market, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - On July 8, 2025, the company further lowered its revenue forecast, attributing it to slower LAL utilization and adoption challenges, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2] Group 1: Allegations - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2] - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [2] - Defendants' statements regarding LifeMD's business, operations, and prospects are claimed to be materially false and misleading [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]